Articles

Original Article

Relative Efficacy of ²²⁵Ac-PSMA-617 and ¹⁷⁷Lu-PSMA-617 in Prostate Cancer Based on Subcellular Dosimetry

Hwan Lee

Mol Imaging Radionucl Ther 2022; 31: 1-6 DOI: 10.4274/mirt.galenos.2021.63308 PMID:35114745

Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry

Levent Kabasakal
Türkay Toklu
Nami Yeyin
Emre Demirci
Mohammad Abuqbeitah
Meltem Ocak
Aslan Aygün
Emre Karayel
Hüseyin Pehlivanoglu
Nalan Alan Selçuk

Mol Imaging Radionucl Ther 2017; 26: 62-68 DOI: 10.4274/mirt.08760 PMID:28613198

Initial Findings on the Use of [²²⁵Ac]Ac-DOTATATE Therapy as a Theranostic Application in Patients with Neuroendocrine Tumors

Emre Demirci
Nalan Alan Selçuk
Gamze Beydağı
Meltem Ocak
Türkay Toklu
Kaan Akçay
Levent Kabasakal

Mol Imaging Radionucl Ther 2023; 32: 226-232 DOI: 10.4274/mirt.galenos.2023.38258 PMID:37870290

Interesting Image

Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action

Majid Assadi
Seyed Javad Rekabpour
Abdullatif Amini
Habibollah Dadgar
Reza Nemati
Ali Gholamrezanezhad
Iraj Nabipour
Esmail Jafari
Hojjat Ahmadzadehfar

Mol Imaging Radionucl Ther 2021; 30: 107-109 DOI: 10.4274/mirt.galenos.2020.69783 PMID:34082512

Almost Complete Response with a Single Administration ²²⁵Ac-DOTATATE in a Patient with a Metastatic Neuroendocrine Tumor of Unknown Primary

Nalan Alan Selçuk
Emre Demirci
Meltem Ocak
Türkay Toklu
Selçuk Ergen
Levent Kabasakal

Mol Imaging Radionucl Ther 2022; 31: 139-141 DOI: 10.4274/mirt.galenos.2022.64497 PMID:35771003

About Journal

Forms

Useful Links

Latest Update: 16.04.2024